Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VREX vs AVNS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VREX Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–5 Matrix Metrics)

VREX Overall Winner 6-Pillar Tally: VREX 3 – 2 AVNS (1 Tie) Matrix Metrics: VREX 5 – 5 AVNS

As of Nov 16, 2026, Varex Imaging Corporation (VREX) is the stronger overall head-to-head candidate over Avanos Medical, Inc. (AVNS) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). VREX carries a Unified Composite Score of 50.0/100 (HOLD) at $18.21 (16.9x Forward P/E, 8.3% operating margin), whereas AVNS carries 56.7/100 (HOLD) at $24.99 (20.0x Forward P/E, 5.4% operating margin).

  • Composite vs. Pillar Nuance: While AVNS currently prints a higher short-term Unified Composite Score (56.7/100 HOLD vs. VREX 50.0/100 HOLD), VREX captures the overall institutional head-to-head verdict (5–5 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (8.3% vs. 5.4% operating margin) and revenue trajectory (+3.7% vs. +8.8% YoY).
  • Technical & Structure Timing Caution: VREX is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 35.5); meanwhile AVNS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 57.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VREX vs AVNS
VREX NASDAQ Head-to-Head Winner
Varex Imaging Corporation Common Stock
Electronic Components, Nec
$18.21
+0.64% 1D
Market Cap $771.6M
TTM Revenue $865M
Forward P/E 16.9x
Beta / 30D Vol 0.74β · 5% Vol
Unified Composite Score
50.0 / 100 HOLD
Tech 47.0 Fund 50.0 Flow 50.0 Mom 56.1
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -0.2%) with fading momentum, RSI 36
RSI-14: 35.5 · SMA20: $18.40 · SMA50: $18.44
AVNS NYSE
Avanos Medical, Inc.
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$24.99
+0.04% 1D
Market Cap $1.2B
TTM Revenue $716M
Forward P/E 20.0x
Beta / 30D Vol 1.22β · 6% Vol
Unified Composite Score
56.7 / 100 HOLD
Tech 75.0 Fund 59.0 Flow 50.0 Mom 46.9
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 57
RSI-14: 57.0 · SMA20: $24.93 · SMA50: $24.90

6-Pillar Scorecard Institutional Category Breakdown (VREX 3 – 2 AVNS)

Columns: Metric · VREX · AVNS
1. Valuation Multiples VREX
Forward P/E 16.9x 20.0x
Trailing P/E 34.3x 30.7x
PEG Ratio 6.30x N/M
EV / Revenue 0.9x 1.6x
2. Growth & Scale AVNS
Revenue Growth (YoY) +3.7% +8.8%
Earnings Growth (YoY) +453.4% -21.7%
TTM Revenue (USD) $865M $716M
Market Cap $771.6M $1.2B
3. Profitability & Quality VREX
Gross Margin 34.3% 50.0%
Operating Margin 8.3% 5.4%
Net Profit Margin 2.6% -10.4%
Return on Equity (ROE) 4.6% -9.2%
4. Balance Sheet & Cash Flow VREX
Cash Generation (TTM) $100M EBITDA $56M EBITDA
Cash Flow Margin 11.5% EBITDA Mgn 7.8% EBITDA Mgn
Net Cash / Leverage $11.78 Book/Sh · 4.6% ROE $16.76 Book/Sh · -9.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 112.0% (18th %ile) 33.0% (50th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Distribution NEUTRAL · Neutral
6. R&D & Supply-Chain Moat AVNS
OpEx & R&D Intensity 26.0% of Rev ($225M) 44.6% of Rev ($319M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VREX (5) vs AVNS (5)
Institutional Metric VREX AVNS Criterion Row Edge
Market Capitalization
Scale
$771.6M $1.2B Larger Scale AVNS
Trailing P/E Ratio
Valuation
34.3x 30.7x Lower Multiple AVNS
Forward P/E Ratio
Valuation
16.9x 20.0x Lower Multiple VREX
Revenue Growth (YoY)
Growth
+3.7% +8.8% Higher Growth AVNS
Operating Margin (TTM)
Profitability
8.3% 5.4% Higher Margin VREX
Net Profit Margin
Profitability
2.6% -10.4% Higher Margin VREX
Return on Equity (ROE)
Capital Efficiency
4.6% -9.2% Higher ROE VREX
52-Week Range Position
Momentum
96% ($9–$19) 97% ($9–$25) Stronger Trend AVNS
Beta / 30D Volatility
Risk Regime
0.74β · 5% Vol 1.22β · 6% Vol Lower Realized Risk VREX
Unified Institutional Score
Composite Signal
50.0 / 100 (HOLD) 56.7 / 100 (HOLD) Higher Composite AVNS
Trailing 12M Revenue (USD)
Operating Scale
$865M $716M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
34.3% 50.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
6.30x PEG · 0.9x EV/Rev N/M PEG · 1.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$100M EBITDA ($11.78 Book/Sh · 4.6% ROE) $56M EBITDA ($16.76 Book/Sh · -9.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VREX +5.14 pp
VREX: +5.3% · AVNS: +0.16%
3M Horizon AVNS +12.06 pp
VREX: -10.93% · AVNS: +1.13%
6M Horizon AVNS +114.72 pp
VREX: -23.96% · AVNS: +90.76%
1Y Horizon AVNS +121.83 pp
VREX: -9.15% · AVNS: +112.68%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VREX vs AVNS. Trailing 12-month operating profitability (VREX 8.3% vs AVNS 5.4%) and valuation multiples (VREX 16.9x vs AVNS 20.0x Forward P/E) are benchmarked directly in Pillar 4 below.

VREX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$865M
Gross Margin34.3%
Op. Margin8.3%
ROE / Fwd P/E4.6% · 16.9x
AVNS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$716M
Gross Margin50.0%
Op. Margin5.4%
ROE / Fwd P/E-9.2% · 20.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VREX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 112.0%
IV Percentile 18th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VREX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AVNS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 33.0%
IV Percentile 50th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AVNS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VREX Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $771.6M market capitalization and 8.3% operating margin.
OpEx & R&D Reinvestment 26.0% of Rev ($225M)
90D Engineering Disclosures 0 Published
AVNS Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $1.2B market capitalization and 5.4% operating margin.
OpEx & R&D Reinvestment 44.6% of Rev ($319M)
90D Engineering Disclosures 0 Published

Investor FAQ VREX vs AVNS Key Questions & Quantitative Answers

As of Nov 16, 2026, Varex Imaging Corporation (VREX) is the stronger overall head-to-head candidate over Avanos Medical, Inc. (AVNS) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). VREX carries a Unified Composite Score of 50.0/100 (HOLD) at $18.21 (16.9x Forward P/E, 8.3% operating margin), whereas AVNS carries 56.7/100 (HOLD) at $24.99 (20.0x Forward P/E, 5.4% operating margin). Composite vs. Pillar Nuance: While AVNS currently prints a higher short-term Unified Composite Score (56.7/100 HOLD vs. VREX 50.0/100 HOLD), VREX captures the overall institutional head-to-head verdict (5–5 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (8.3% vs. 5.4% operating margin) and revenue trajectory (+3.7% vs. +8.8% YoY). Technical & Structure Timing Caution: VREX is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 35.5); meanwhile AVNS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 57.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AVNS leads the Growth & Scale pillar: VREX posts +3.7% YoY revenue growth and +453.4% YoY earnings growth on $865M TTM revenue (34.3% gross margin, 8.3% operating margin), compared with AVNS at +8.8% YoY revenue growth and -21.7% YoY earnings growth on $716M TTM revenue (50.0% gross margin, 5.4% operating margin). On trailing 12-month operating scale, VREX generates $865M in USD-normalized revenue versus $716M for AVNS. In operating R&D and SG&A reinvestment, VREX deploys 26.0% of Rev ($225M) (0 90-day corporate R&D disclosures) versus 44.6% of Rev ($319M) (0 disclosures) for AVNS.

VREX screens cheaper on headline valuation multiples. VREX trades at 16.9x Forward P/E, 34.3x Trailing P/E, 6.30x PEG, and 0.9x EV/Revenue (11.5% EBITDA margin), whereas AVNS trades at 20.0x Forward P/E, 30.7x Trailing P/E, N/M PEG, and 1.6x EV/Revenue (7.8% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VREX (4.6% ROE) versus AVNS (-9.2% ROE) capital efficiency.

In options market volatility and institutional positioning, VREX carries 112.0% implied volatility (18th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.74β · 5% Vol realized risk). By comparison, AVNS carries 33.0% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.22β · 6% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.